192 related articles for article (PubMed ID: 36039063)
1. Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer
Jang Y; Lee WS; Sai S; Kim JY; Kim JK; Kim EH
Oncol Lett; 2022 Oct; 24(4):338. PubMed ID: 36039063
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines.
Lee WS; Jang Y; Cho A; Kim YB; Bu YH; Yang S; Kim EH
Exp Ther Med; 2023 Aug; 26(2):363. PubMed ID: 37408858
[TBL] [Abstract][Full Text] [Related]
3. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma
Davidi S; Jacobovitch S; Shteingauz A; Martinez-Conde A; Braten O; Tempel-Brami C; Zeevi E; Frechtel-Gerzi R; Ene H; Dor-On E; Voloshin T; Tzchori I; Haber A; Giladi M; Kinzel A; Weinberg U; Palti Y
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740624
[TBL] [Abstract][Full Text] [Related]
4. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
5. Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.
Gkika E; Grosu AL; Macarulla Mercade T; Cubillo Gracián A; Brunner TB; Schultheiß M; Pazgan-Simon M; Seufferlein T; Touchefeu Y
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326718
[TBL] [Abstract][Full Text] [Related]
6. Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling.
Kim EH; Lee WS; Oh HK
Transl Cancer Res; 2022 Aug; 11(8):2553-2561. PubMed ID: 36093532
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of Doxorubicin with TTFields and radiation: newer approaches to combat lung cancer.
Lee WS; Kim EH
Am J Cancer Res; 2022; 12(6):2673-2685. PubMed ID: 35812042
[TBL] [Abstract][Full Text] [Related]
8. A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
Li X; Liu K; Xing L; Rubinsky B
Radiol Oncol; 2023 Sep; 57(3):279-291. PubMed ID: 37665740
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3.
Kim JY; Jo Y; Oh HK; Kim EH
Am J Cancer Res; 2020; 10(10):3475-3486. PubMed ID: 33163284
[TBL] [Abstract][Full Text] [Related]
10. Tumor treating fields: narrative review of a promising treatment modality for cancer.
Kutuk T; Atak E; La Rosa A; Kotecha R; Mehta MP; Chuong MD
Chin Clin Oncol; 2023 Dec; 12(6):64. PubMed ID: 37953242
[TBL] [Abstract][Full Text] [Related]
11. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E
Elife; 2023 Nov; 12():. PubMed ID: 37955637
[TBL] [Abstract][Full Text] [Related]
12. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.
Tanzhu G; Chen L; Xiao G; Shi W; Peng H; Chen D; Zhou R
Cell Death Discov; 2022 Oct; 8(1):416. PubMed ID: 36220835
[TBL] [Abstract][Full Text] [Related]
13. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
[TBL] [Abstract][Full Text] [Related]
14. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
15. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
Nitta RT; Luo EJ; Lim M; Li G
J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
[TBL] [Abstract][Full Text] [Related]
16. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of tumor-treating fields in preclinical glioma models.
Silginer M; Weller M; Stupp R; Roth P
Cell Death Dis; 2017 Apr; 8(4):e2753. PubMed ID: 28425987
[TBL] [Abstract][Full Text] [Related]
18. Tumor treating fields: concept, evidence and future.
Pless M; Weinberg U
Expert Opin Investig Drugs; 2011 Aug; 20(8):1099-106. PubMed ID: 21548832
[TBL] [Abstract][Full Text] [Related]
19. Real-Time Monitoring of the Effect of Tumour-Treating Fields on Cell Division Using Live-Cell Imaging.
Le HT; Staelens M; Lazzari D; Chan G; Tuszyński JA
Cells; 2022 Aug; 11(17):. PubMed ID: 36078119
[TBL] [Abstract][Full Text] [Related]
20. Tumor treating fields: a new frontier in cancer therapy.
Davies AM; Weinberg U; Palti Y
Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]